Fundraising Fox
Angiex
Cambridge, US · Founded 2015 · Delaware corporation · 10 employees on LinkedIn · 3 known investors
Find your way into Angiex
Sign up to find every way you can get introduced to Angiex
- Your email: who you already know at Angiex, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Angiex team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells. Its lead asset, AGX101, is a TM4SF1-directed ADC in Phase 1 clinical development for advanced solid tumors.
Founders & leadership
Angiex was founded in 2015 by Paul Jaminet.
Board
EA
Errik AndersonBoard director
ID
FH
HG
Haijing GuoBoard director
Investors · 3
K5 Globallisted by K5 GlobalSan Francisco · $1M – $3M
How we know: K5 Global's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$24.9M disclosed across 2 rounds · 2017–2025
▶$22MraisedSep 2025 · 137 investors · BiotechnologyRule 506(c)
▶$22MraisedSep 2025 · 137 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jonathan AdamsDirector
- Errik AndersonDirector
- Jason CammDirector
- Fabian HansenDirector
- Paul JaminetExecutive Officer, Director
- Amal AminDirector
- Haijing GuoDirector
- Iain DukesDirector
- Tina NeelDirector
- Offering amount
- $28.4M
- Amount sold
- $22M
- Finders' fees
- $2.4M
- Placement agents
- 10220 SW Greenburg Road, Suite 380
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.9MraisedJul 2017 · 3 investors · BiotechnologyRule 506(b)
▶$2.9MraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul JaminetExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2.9M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
arGEN-XThe company develops therapies for people with severe autoimmune diseases.
Companies working in the same space as Angiex.
Frequently asked questions
- What does Angiex do?
- Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells. Its lead asset, AGX101, is a TM4SF1-directed ADC in Phase 1 clinical development for advanced solid tumors.
- Who founded Angiex?
- Angiex was founded by Paul Jaminet in 2015.
- Who are Angiex's investors?
- Angiex's investors include Green Meadow Ventures, K5 Global, OrbiMed.
- How much funding has Angiex raised?
- Angiex has disclosed $24.9M raised across 2 rounds.
- Where is Angiex headquartered?
- Angiex is headquartered in Cambridge, US.